‘Broad Daylight Dacoity’, Says Supreme Court on Overpricing of Essential Cancer Drugs
- The Supreme Court criticized cancer-drug pricing after hearing that a medicine costing retailers Rs 2,700 had an MRP of Rs 27,000.
- The Bench described the pricing as “broad daylight dacoity” and questioned how patients could be charged such high amounts.
- The matter raised concerns about medicine pricing and calls for stronger price controls and affordable medicines.
- The matter was scheduled for another hearing on September 29.
26 Articles
26 Articles
Blatant daylight dacoity: SC on 10-fold gap in cancer drug prices
The Supreme Court on Tuesday questioned the disparity in drug pricing with essential cancer drugs sold to consumers at a whopping ₹27,000 when the price at which it is sold to retailers is only ₹2,700, observing that this amounts to “broad daylight dacoity” and asked the government authorities why they fail to act on this crucial issue
Broad daylight dacoity: SC questions authorities’ silence on overpricing of essential cancer drugs - The Tribune
Pointing out that one drug carried an MRP of Rs 27,000 despite being supplied to retailers for Rs 2,700, Bench says ‘It’s very surprising that the authorities who are supposed to take action on this are silent’
The Supreme Court has expressed strong displeasure over the huge difference in the prices of cancer medicines and the in-house pharmacies of hospitals charging higher prices from patients.
Coverage Details
Bias Distribution
- 72% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
